MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$33M |
| 2 |
ARS Pharmaceuticals
SPRY
|
+$15.8M |
| 3 |
Janux Therapeutics
JANX
|
+$12.7M |
| 4 |
United Therapeutics
UTHR
|
+$12.3M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$26.9M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$24.4M |
| 3 |
Disc Medicine
IRON
|
+$22M |
| 4 |
Scholar Rock
SRRK
|
+$18M |
| 5 |
Akero Therapeutics
AKRO
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q1 2025 Portfolio in Review
As of Q1 2025, MPM BioImpact held 53 positions worth $582M, down 17% from $704M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
MPM BioImpact's Q1 2025 filing shows 6 new, 26 increased, 8 reduced and 10 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M. The largest sale was Insmed, an estimated $26.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- MPM BioImpact's largest Q1 2025 buy was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M.
- MPM BioImpact added most to Janux Therapeutics in Q1 2025, an estimated $12.7M increase.
- MPM BioImpact's biggest Q1 2025 reduction was ALX Oncology, cutting an estimated $1.01M.
- MPM BioImpact fully exited Insmed in Q1 2025, selling an estimated $26.9M.
- MPM BioImpact's ten largest holdings make up 48% of its $582M portfolio in Q1 2025.
- MPM BioImpact opened 6 new positions and closed 10 in Q1 2025.
- MPM BioImpact's portfolio value fell 17% quarter-over-quarter to $582M.
Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.